Profile for Australia Patent: 2011248624

US Patent Family Members and Approved Drugs for Australia Patent: 2011248624

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	May 2, 2027	Bausch And Lomb Inc	XIPERE	triamcinolone acetonide

Key insights for pharmaceutical patentability - Australia patent AU2011248624

Last updated: April 23, 2026

What Is the Patent Scope and Claim Coverage for AU2011248624 in Australia?

AU2011248624 is an Australian patent application/patent record that covers a medicinal invention. A complete, accurate scope-and-claims analysis requires the published specification and the actual claim set (including claim numbering, dependencies, claim categories, and any amended claim versions). Those documents are not present in the information provided in this chat, so a full claim-by-claim landscape and scope mapping cannot be produced correctly.

What Claims Are Listed in AU2011248624?

No claim text or claim set content is provided here for AU2011248624. Without the claim language (and any granted-versus-filed claim differences), the request cannot be satisfied with the precision required for patent-landscape work.

What Is the Likely Claim Scope (Composition, Use, Process) for AU2011248624?

No invention summary, independent-claim structure, or key technical descriptors are provided for AU2011248624. Without the specification and claims, any “likely” scope would risk being wrong and would not meet a hard-data patent analyst standard.

How Does AU2011248624 Sit Against the Australian Prior-Art Landscape?

A prior-art comparison requires: (1) the drug substance identity, (2) the exact claim elements, (3) publication dates for relevant documents, and (4) citation lists or search report content tied to the Australian file. None of those inputs are available in this chat.

Are There Granted Rights in Australia for AU2011248624?

Status (application, granted, lapsed, ceased, amended) is not provided here. Australian claim scope differs materially between filing and grant, so status is essential for landscape conclusions.

What Other Patents Form the Closest Australia Cluster?

A “closest-patents” map depends on INPADOC-family links, assignee, CPC/IPC classes, and citation networks. No family, assignee, or publication/citation data is provided for AU2011248624.

Key Takeaways

• AU2011248624 scope and claim coverage cannot be analyzed to a correct, claim-accurate level without the published Australian specification and claim text.
• No claim set, invention description, grant status, or citation/family data is present in the provided inputs, so no reliable landscape mapping can be produced.

FAQs

1. Can the scope be determined without claim text?
   No. Scope work for a specific AU publication needs the exact independent and dependent claim language.

2. Does the landscape differ between application and grant?
   Yes. Claim amendments at grant can materially change coverage.

3. What documents are required for an Australian patent landscape around a single AU number?
   The AU publication (specification and claims), legal status, and family/citation data.

4. Can I approximate scope from the drug name only?
   Not to a patent-analyst standard; composition, polymorph, formulation, dosing regimen, and use claims vary widely.

5. Is it possible to identify close competitors without citation data?
   Only at a high level; a rigorous landscape needs citation networks, classifications, and family links.

---

References (APA)

No sources are cited because no AU2011248624 publication/specification, claim set, or legal-status documents were provided in this chat.